International Scholarly Research Notices

International Scholarly Research Notices / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 132020 | https://doi.org/10.1155/2014/132020

Rihana Parveen Shaik, Srinivasa Babu Puttagunta, Chandrasekar Kothapalli Bannoth, Bala Sekhara Reddy Challa, "Analytical Method Development and Validation of Solifenacin in Pharmaceutical Dosage Forms by RP-HPLC", International Scholarly Research Notices, vol. 2014, Article ID 132020, 5 pages, 2014. https://doi.org/10.1155/2014/132020

Analytical Method Development and Validation of Solifenacin in Pharmaceutical Dosage Forms by RP-HPLC

Academic Editor: J. Esteve-Romero
Received04 Jan 2014
Accepted12 Feb 2014
Published16 Apr 2014

Abstract

A new, accurate, precise, and robust HPLC method was developed and validated for the determination of solifenacin in tablet dosage form. The chromatographic separation was achieved on an Inertsil ODS 3V C18 (150 mm × 4.6 mm, 5 μm) stationary phase maintained at ambient temperature with a mobile phase combination of monobasic potassium phosphate (pH 3.5) containing 0.1% triethylamine and methanol (gradient mode) at a flow rate of 1.5 mL/min, and the detection was carried out by using UV detector at 220 nm. The performance of the method was validated according to the present ICH guidelines.

1. Introduction

Solifenacin succinate is a competitive muscarinic acetylcholine receptor antagonist used in the treatment of overactive bladder with or without urge incontinence. Chemically it is 1-azabicyclo[2.2.2]oct-8-yl(1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2 carboxylate shown in Figure 1.

The molecular formula of solifenacin succinate is C23H26N2O2 with its molecular weight 362.46. Solifenacin is extensively metabolized in the liver. The metabolites observed as one pharmacologically active metabolite (4R-hydroxy solifenacin), and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) occurring at low concentrations in human plasma after oral dosing. After oral administration of vesicare to healthy volunteers, peak plasma levels (Cmax) of solifenacin are reached within 3 to 8 hours after administration and at steady state ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg vesicare tablets, respectively. The terminal elimination half-life of SF is approximately 45–68 hours. Solifenacin is approximately 98% (in vivo) bound to human plasma proteins, principally to alpha-1-acid glycoprotein [110].

Literature survey reveals that quantification of solifenacin in human plasma [11, 12], rat plasma [13], pharmaceutical compounds [1417], and industrial waste streams [18] was reported. These methods were reported by using LC-MS/MS [11, 12, 18], HPLC [1316], and HPTLC [17]. Among all, quantification of solifenacin by LC-MS/MS in biological matrices [1113] was proved best results.

The reported HPLC methods [1316] have some drawbacks in terms of ruggedness, reproducibility, and sensitivity in long run. The main goal of the present study is to develop and validate the novel simple, higher sensitive, selective, rugged, and reproducible analytical method for quantitative determination of solifenacin in pharmaceutical compounds by HPLC. The developed method would be applied in finished product and in quality control.

2. Experimental

2.1. Instrumentation

The Waters HPLC system equipped with autosampler and UV or DAD was used for method development and method validation. The output signal was monitored and processed by using Empower software.

2.2. Materials

Solifenacin succinate bulk drug was made available from Genova Labs, Bangalore; orthophosphoric acid (85%), potassium phosphate monobasic, methanol, and acetonitrile were obtained from Merk. Commercially available solifenacin tablets were used for the dosage form analysis. All chemicals and reagents used were of HPLC grade; Milli-Q-water was used throughout the experiment. The pharmaceutical dosage form assayed in the study is test formulation containing 5 mg of solifenacin.

2.2.1. Mobile Phase Preparation

Solution A. About 1.36 g of potassium phosphate monobasic was dissolved into 1000 mL of water. Then 1 mL of triethylamine was added and mixed well. Finally pH adjusted with orthophosphoric acid (85%) was mixed and degas-filtered.

Solution B. This contained methanol. Gradient program was shown in Table 1.


Mobile phase gradient program
Time (min)A%B%Flow rate (mL/min)Gradient program

0.0050501.5Initial
8.0030701.5Linear
8.515851.5Linear
13.015851.5Isocratic
13.150501.5Linear
16.050501.5Isocratic

Sample Solvent. This contained mobile phase A : B: 20 : 80 (% v/v).

2.3. Chromatographic Conditions

The mobile phase used was mixture of monobasic potassium phosphate containing 0.1% triethylamine and methanol in the ratio of gradient elution at a flow rate of 1.5 mL/min and the injection volume was 10 μL. The analytical column used was Inertsil ODS 3V C18 (150 mm × 4.6 mm, 5 μm) at ambient temperature. The detection was carried out at a wavelength of 220 nm for a run time of 16 min. The retention time of solifenacin was found to be 5.12 min.

2.4. Preparation of Standard Stock Solution

Accurately weigh and transfer 50 mg of solifenacin succinate working standard into two separate 100 mL clean dry volumetric flasks; add diluent and sonicate to dissolve it completely and make up volume to the mark with the same solvent (sample solvent solution). Further pipette 10.0 mL solifenacin of the above stock solution into a 50 mL volumetric flask and dilute it up to the mark with diluent.

2.4.1. Assay of Pharmaceutical Dosage Form: Sample Preparation

Take 20 tablets and calculate the average weight. Crush the tablets and accurately weigh 50 mg of tablet powder and transfer it into 100 mL volumetric flask and add sample solvent to extract solifenacin by ultrasonication for 10 min. The resultant mixture was filtered through 0.45 μ filter. From this, take 10.0 mL and transfer it to 50 mL volumetric flask and make up the volume using mobile phase as shown in Table 2.


Assay (mg/g)   × standard weight × sample dilution × %P × 1000
  × standard dilution × sample weight × 100

Assay (%)Assay (mg/g) × 100
Theoretical weight (mg/g)

Label claim (%)   × standard weight × sample dilution × %P × 100
  × standard dilution ×     × 100 × LC

: area of sample in blend assay.
: area of sample in drug product assay.
: mean area of standard.
Spl: drug substance sample for assay.
Spt: drug substance standard for assay.
%P: percentage of potency (as is basis).
LC: label claim in mg.

3. Results and Discussion

3.1. Optimization of Chromatographic Conditions

Several HPLC methods were developed for the estimation of solifenacin using methanol, water, acetonitrile and phosphate, acetate, and OPA buffer. Hence we have selected potassium phosphate buffer and Inertsil ODS 3V C18 (150 mm × 4.6 mm, 5 μm) column to decrease the retention time and to obtain symmetric peaks having good resolution. Different trails were performed using different proportions of potassium phosphate buffer having different pH with methanol and acetonitrile. The mobile phase containing monobasic potassium phosphate pH 3.5 containing 0.1% triethylamine and methanol (adjusted to pH 3.5): (gradient programme) was found to be satisfactory and gave symmetric and well-resolved peak for solifenacin.

The retention time of solifenacin was found to be 5.12. The USP plate count and tailing factor were 6984 and 1.34 for solifenacin. The standard chromatogram was shown in Figure 2.

3.2. Validation of Proposed Method

The proposed method was validated according to the International Conference on Harmonization (ICH) guidelines [19].

3.3. Linearity

Linearity test solutions of solifenacin (10–100 (μg/mL)) were prepared from the stock solution at five different concentration levels. The calibration curves were constructed by plotting peak areas versus their corresponding concentrations. The slope, -intercept, and correlation coefficient of the calibration curve were calculated. The correlation coefficient was found to be 0.999 and the calibration curve for solifenacin is given in Figure 3.

3.4. Precision

Precision was evaluated by injecting five replicate injections of solifenacin of standard concentration under the same chromatographic conditions and calculated by the %RSD. The %RSD indicates that the developed method is repeatable. The %RSD for assay of solifenacin was found to be 1.37. The results are shown in Table 3.


S. No.PrecisionIntermediate precision

13791436524
23652337548
33725436325
43702335698
53695536324

Average3713436484
Standard deviation510.02671.26
%RSD1.371.84

3.5. Intermediate Precision/Ruggedness

The intermediate precision of the method was checked by determining precision on the same instrument, using the same chromatographic conditions in different day. The %RSD of solifenacin was found to be below 2 even when it is performed in different day. The method is said to be precise with respect to the criteria of the intermediate precision. The results are given in Table 3.

3.6. Accuracy

In order to judge the quality and applicability of method the recovery analysis was performed at three levels 50%, 100%, and 150% by standard addition method. The % recoveries for solifenacin were calculated by injecting the samples and it was found to be within the limits; the results are given in Table 4.


Analyte% LevelNominal value (mg)Found (mg)% RecoveryMean % recovery

Solifenacin 50%2.52.3594.0095.38
100%54.9899.60
150%7.56.9492.53

3.6.1. Robustness

The robustness as a measure of method capability to remain unaffected by small, but deliberate changes in chromatographic conditions was studied by testing influence of small changes in mobile phase composition (10% absolute change in organic phase) and flow rate (±0.2 mL/min). The USP plate count and USP tailing were within the limits. So, the method was found to be robust with respect to variability in all robust conditions.

3.6.2. LOD and LOQ

The LOD and LOQ of solifenacin were determined by using the signal to noise approach as defined in ICH guidelines. The concentration with signal to noise ratio of LOD and LOQ at S/N was 3 and 10, respectively. The results are given in Table 5.


LOD ( g/mL)LOQ ( g/mL)LOD ratioLOQ ratio

Solifenacin 0.0210.00 3.1414.16

3.6.3. Assay of Pharmaceutical Formulation

The proposed validated method was successfully applied to determine solifenacin in its tablet dosage form. The result obtained for solifenacin was comparable with the corresponding labeled amounts and they are given in Table 6.


Label claim (mg)Amount found (mg)% Assay

Solifenacin 5.04.8597.00

4. Conclusion

The present work refers to the fact that the most accurate, precise, and robust HPLC method was developed and validated for estimation of solifenacin in pharmaceutical dosage form in accordance with the ICH parameters. The method was validated and found to be simple, accurate, and precise. Percentage of recovery shows that the method is free from interference of the excipients used in the formulation. Therefore, the proposed method can be used for routine analysis of solifenacin in its dosage form.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors are very thankful to Adcock Ingram, Genova Research Labs, Bangalore, for providing facilities and equipment and for providing samples.

References

  1. F. J. Morales-Olivas and L. Estañ, “Solifenacin pharmacology,” Archivos Espanoles de Urologia, vol. 63, no. 1, pp. 43–52, 2010. View at: Google Scholar
  2. O. Doroshyenko and U. Fuhr, “Clinical pharmacokinetics and pharmacodynamics of solifenacin,” Clinical Pharmacokinetics, vol. 48, no. 5, pp. 281–302, 2009. View at: Publisher Site | Google Scholar
  3. S. Hoffstetter and C. L. Fah, “Solifenacin succinate for the treatment of overactive bladder,” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 3, pp. 345–350, 2009. View at: Publisher Site | Google Scholar
  4. M. E. Kuipers, W. J. J. Krauwinkel, H. Mulder, and N. Visser, “Solifenacin demonstrates high absolute bioavailability in healthy men,” Drugs in R and D, vol. 5, no. 2, pp. 73–81, 2004. View at: Publisher Site | Google Scholar
  5. U. L. Roberti Maggiore, S. Salvatore, F. Alessandri et al., “Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 11, pp. 1387–1408, 2012. View at: Publisher Site | Google Scholar
  6. T. Uchida, W. J. Krauwinkel, H. Mulder, and R. A. Smulders, “Food does not affect the pharmacokinetic of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial,” British Journal of Clinical Pharmacology, vol. 58, no. 1, pp. 4–7, 2004. View at: Publisher Site | Google Scholar
  7. S. Yamada, S. Kuraoka, A. Osano, and Y. Ito, “Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding,” International Neurourology Journal, vol. 16, no. 3, pp. 107–115, 2012. View at: Publisher Site | Google Scholar
  8. S. Maruyama, H. Tsukada, S. Nishiyama et al., “In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 774–781, 2008. View at: Publisher Site | Google Scholar
  9. M. Kuipers, R. Smulders, W. Krauwinkel, and T. Hoon, “Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment,” Journal of Pharmacological Sciences, vol. 102, no. 4, pp. 405–412, 2006. View at: Publisher Site | Google Scholar
  10. E. Callegari, B. Malhotra, P. J. Bungay et al., “A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder,” British Journal of Clinical Pharmacology, vol. 72, no. 2, pp. 235–246, 2011. View at: Publisher Site | Google Scholar
  11. J. Macek, P. Ptacek, and J. Klima, “Determination of solifenacin in human plasma by liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 878, no. 31, pp. 3327–3330, 2010. View at: Publisher Site | Google Scholar
  12. H. N. Mistri, A. G. Jangid, A. Pudage, D. M. Rathod, and P. S. Shrivastav, “Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective α1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 876, no. 2, pp. 236–244, 2008. View at: Publisher Site | Google Scholar
  13. T. Yanagihara, T. Aoki, Y. Soeishi, T. Iwatsubo, and H. Kamimura, “Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 859, no. 2, pp. 241–245, 2007. View at: Publisher Site | Google Scholar
  14. S. R. Krishna, B. M. Rao, and N. S. Rao, “A validated rapid stability-indicating method for the determination of related substances in Solifenacin Succinate by ultra-fast liquid chromatography,” Journal of Chromatographic Science, vol. 48, no. 10, pp. 807–810, 2010. View at: Google Scholar
  15. D. Desai, G. Patel, N. Shukla, and S. Rajput, “Development and validation of stability-indicating HPLC method for solifenacin succinate: isolation and identification of major base degradation product,” Acta Chromatographica, vol. 24, no. 3, pp. 399–418, 2012. View at: Publisher Site | Google Scholar
  16. B. V. Rami Reddy, B. Srinivasa Reddy, N. V. V. S. S. Raman, K. S. Reddy, and C. Rambabu, “Development and validation of a specific stability indicating high performance liquid chromatographic methods for related compounds and assay of solifenacin succinate,” Journal of Chemistry, vol. 2013, Article ID 412353, 10 pages, 2013. View at: Publisher Site | Google Scholar
  17. D. J. Desai, G. Patel, D. Ruikar, R. A. Jain, and S. J. Rajput, “Development and validation of stability-indicating HPTLC method of solifenacin succinate,” Asian Journal of Pharmaceutical and Biological Research, vol. 1, no. 3, pp. 310–316, 2011. View at: Google Scholar
  18. A. M. Deegan, M. Cullen, M. Oelgemöller, K. Nolan, J. Tobin, and A. Morrissey, “A SPE-LC-MS/MS method for the detection of low concentrations of pharmaceuticals in industrial waste streams,” Analytical Letters, vol. 44, no. 17, pp. 2808–2820, 2011. View at: Publisher Site | Google Scholar
  19. ICH Guidelines, “Validation of analytical procedures: text and methodology,” ICH Q2(R1), 2005. View at: Google Scholar

Copyright © 2014 Rihana Parveen Shaik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views5255
Downloads808
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.